Home > Result Summaries: Compounds > SB656933 Result Summaries: SB656933 GSKStudy ID Phase Title Summary (Download) 110399 phase 2 A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients with Cystic Fibrosis. (0 citation(s)) CR219039 Phase 1 A dose ranging study to assess the effect of pre-treatment with a single dose of inhaled fluticasone propionate (2 mg, 0.5 mg) on lung inflammation following challenge with inhaled ozone and intermittent exercise in healthy volunteers, relative to placebo. (0 citation(s)) CUC111342 phase 2 An open label, 7-day repeat dose study to evaluate the pharmacodynamics of SB-656933-AAA in patients with Ulcerative Colitis. (0 citation(s))
